Published in Ann Hepatol on January 01, 2009
Omega-3 vs Very Low Calorie Diet for Liver Size Reduction | NCT03132662
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology (2015) 2.49
Lack of exercise is a major cause of chronic diseases. Compr Physiol (2012) 2.19
Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat Mon (2011) 1.99
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.88
Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog Neurobiol (2010) 1.38
Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol (2012) 1.17
Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol (2013) 1.12
Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One (2012) 1.08
Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent. Hepatology (2013) 1.04
Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes (2013) 1.01
Transcriptional co-activator p300 maintains basal hepatic gluconeogenesis. J Biol Chem (2012) 0.99
The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS One (2015) 0.99
Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice. Hepatology (2011) 0.95
Association between markers of fatty liver disease and impaired glucose regulation in men and women from the general population: the KORA-F4-study. PLoS One (2011) 0.94
Angiogenesis and liver fibrosis. World J Hepatol (2015) 0.93
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol (2013) 0.92
Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. J Gastroenterol (2013) 0.91
Control of Foxo1 gene expression by co-activator P300. J Biol Chem (2013) 0.90
Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol (2013) 0.88
Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. J Nutr Biochem (2014) 0.88
Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. World J Gastroenterol (2014) 0.87
Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. Ann Gastroenterol (2012) 0.86
Mitochondrial dysfunction in obesity-associated nonalcoholic fatty liver disease: the protective effects of pomegranate with its active component punicalagin. Antioxid Redox Signal (2014) 0.85
Independent and supra-additive effects of alcohol consumption, cigarette smoking, and metabolic syndrome on the elevation of serum liver enzyme levels. PLoS One (2013) 0.85
N-3 long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis. PLoS One (2012) 0.85
Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther (2011) 0.84
Inhibition of LXRα/SREBP-1c-Mediated Hepatic Steatosis by Jiang-Zhi Granule. Evid Based Complement Alternat Med (2013) 0.84
Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats. Endocrinology (2013) 0.83
Inflammation in depression: is adiposity a cause? Dialogues Clin Neurosci (2011) 0.83
Serum alanine aminotransferase independently correlates with intrahepatic triglyceride contents in obese subjects. Dig Dis Sci (2014) 0.83
Diagnosing fatty liver disease: a comparative evaluation of metabolic markers, phenotypes, genotypes and established biomarkers. PLoS One (2013) 0.82
Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol (2010) 0.82
The efficacy and safety of traditional chinese medicine (jiang zhi granule) for nonalcoholic Fatty liver: a multicenter, randomized, placebo-controlled study. Evid Based Complement Alternat Med (2013) 0.82
Nuciferine prevents hepatic steatosis and injury induced by a high-fat diet in hamsters. PLoS One (2013) 0.81
An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol (2013) 0.81
Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome. Liver Int (2011) 0.81
Steatosis and steatohepatitis in postmortem material from Northwestern Greece. World J Gastroenterol (2010) 0.80
Developmental Programming of Nonalcoholic Fatty Liver Disease: The Effect of Early Life Nutrition on Susceptibility and Disease Severity in Later Life. Biomed Res Int (2015) 0.78
The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults. Clin Mol Hepatol (2013) 0.78
Obesity, but not ethanol, promotes tumor incidence and progression in a mouse model of hepatocellular carcinoma in vivo. Surg Endosc (2013) 0.78
Combination of diabetes risk factors and hepatic steatosis in Chinese: the Cardiometabolic Risk in Chinese (CRC) Study. PLoS One (2014) 0.78
Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease. Int J Mol Sci (2016) 0.78
Recent Clinical Results of Endoscopic Bariatric Therapies as an Obesity Intervention. Clin Endosc (2017) 0.78
Myeloperoxidase-Hepatocyte-Stellate Cell Cross Talk Promotes Hepatocyte Injury and Fibrosis in Experimental Nonalcoholic Steatohepatitis. Antioxid Redox Signal (2015) 0.77
Gastrointestinal morbidity in obesity. Ann N Y Acad Sci (2014) 0.77
Nonalcoholic fatty liver disease: liver disease: an overlooked complication of diabetes mellitus. Nat Rev Endocrinol (2010) 0.77
Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients. Wien Klin Wochenschr (2014) 0.76
Association between the hyperuricemia and nonalcoholic fatty liver disease risk in a Chinese population: A retrospective cohort study. PLoS One (2017) 0.76
The Effect of Chlorella vulgaris Supplementation on Liver En-zymes, Serum Glucose and Lipid Profile in Patients with Non-Alcoholic Fatty Liver Disease. Health Promot Perspect (2014) 0.76
Pathogenesis and Prevention of Hepatic Steatosis. Gastroenterol Hepatol (N Y) (2015) 0.76
Very Low Density Lipoprotein Assembly Is Required for cAMP-responsive Element-binding Protein H Processing and Hepatic Apolipoprotein A-IV Expression. J Biol Chem (2016) 0.76
Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med (2015) 0.76
Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitis. Afr Health Sci (2016) 0.75
Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice. Int J Mol Sci (2015) 0.75
Effect of miR-146 targeted HDMCP up-regulation in the pathogenesis of nonalcoholic steatohepatitis. PLoS One (2017) 0.75
Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease. PLoS One (2015) 0.75
Prediction and Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) and Identification of Its Associated Factors Using the Classification Tree Method. Iran Red Crescent Med J (2016) 0.75
Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease. Semin Liver Dis (2015) 0.75
Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. Ann Gastroenterol (2016) 0.75
Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. Sci Rep (2016) 0.75
NCX 1000 Alone or in Combination with Vitamin E Reverses Experimental Nonalcoholic Steatohepatitis in the Rat Similarly to UDCA. Int J Hepatol (2011) 0.75
Nonalcoholic Fatty liver disease: its mechanisms and complications. Int J Endocrinol (2013) 0.75
Gastrointestinal Complications of Obesity. Gastroenterology (2017) 0.75
Prevention Mechanism of 2,3,5,4'-Tetrahydroxy-stilbene-2-O-β-D-glucoside on Lipid Accumulation in Steatosis Hepatic L-02 Cell. Pharmacogn Mag (2017) 0.75
Molecular MR Imaging of Myeloperoxidase Distinguishes Steatosis from Steatohepatitis in Nonalcoholic Fatty Liver Disease. Radiology (2017) 0.75
Epidemiology of non-alcoholic fatty liver disease. Dig Dis (2010) 3.44
Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clin Res Hepatol Gastroenterol (2012) 0.84
Influence of lifestyle habits, nutritional status and insulin resistance in NAFLD. Front Biosci (Elite Ed) (2012) 0.78